WO2000037443A1 - Process for preparing arylpiperidine carbinol intermediates and derivatives - Google Patents
Process for preparing arylpiperidine carbinol intermediates and derivatives Download PDFInfo
- Publication number
- WO2000037443A1 WO2000037443A1 PCT/US1999/030365 US9930365W WO0037443A1 WO 2000037443 A1 WO2000037443 A1 WO 2000037443A1 US 9930365 W US9930365 W US 9930365W WO 0037443 A1 WO0037443 A1 WO 0037443A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- structural formula
- trans
- alkyl
- halogen
- Prior art date
Links
- 0 *C1=CCCNC1 Chemical compound *C1=CCCNC1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- This invention relates to arylpiperidine carbinol intermediates and derivatives, as well as methods for their preparation.
- the arylpiperidine carbinols can be represented by the following general structural formula (A).
- paroxetine i.e. , (-)-trans-4-(p-fluorophenyl)-3[[3,4- (methylenedioxy) phenoxy] methyl] -piperidine.
- hydrochloride salt praroxetine HC1
- Paroxetine is useful in managing diseases of the central nervous system. In particular, depression, obsessive compulsive disorder, PMS (premenstrual syndrome), social anxiety disorder, and the like.
- paroxetine has been found to be of particular benefit in treating premature ejaculation, a sexual performance condition affecting men. See, for example, U.S. Patent No. 5,276,042, to Crenshaw et al.
- the pharmacological properties of the substituted arylpiperidine carbinols are primarily expressed by a specific stereo chemical arrangement of the residue. Only the (-)-trans substituted configuration of arylpiperidine carbinols show the desired pharmacodynamic properties. This requires the synthesis and purification of the selected desired enantiomer of the arylpiperidine carbinol.
- a particularly desired enantiomer precursor for preparing pharmacologically active arylpiperidine carbinols is the 4-arylpiperidine-3-carbinol in (-)-trans configuration.
- 4-arylpiperidine-3 -carbinols may exist in four stereo-specific isomers since there are two chiral centers in this molecule. Thus the synthesis of this precursor requires reactions and purification steps favoring the desired enantiomer.
- R can be an alkyl group or the like.
- the present invention provides a process for the synthesis of arylpiperidine carbinol intermediates and derivatives for synthesizing arylpiperidine carbinols in the
- a process for the synthesis of arylpiperidine carbinol intermediates and derivatives is disclosed.
- the inventive process provides for the synthesis of ( ⁇ )-trans intermediate compounds and derivatives, which are useful precursors for simplifying the synthesis of arylpiperidine carbinols in (-)-trans configuration.
- compounds of structural formula (I) can be synthesized by condensing a cinnamonitrile of structural formula:
- each of R 2 and R 3 is as defined in structural formula (I) .
- compounds of structural formula (II) can be synthesized by hydrogenating compounds of structural formula (I).
- a preferred compound of structural formula (I), diethyl-[l-cyanomethyl-l-(4'- fluorophenyl)methyl] -malonate can be synthesized in the form of a substantially pure, crystalline solid having a melting point temperature in the range of about 40° to about 55 °C, preferably in the range of about 45° to about 48 °C.
- the compounds of structural formula (I) and structural formula (II) are useful chemical intermediates for the synthesis of 4-arylpiperidine-3-carbinols in (-)-trans configuration.
- the inventive process advantageously provides compounds of structural formula (II) as a ( ⁇ )-trans configured mixture, thereby avoiding the need to remove cis configured compounds.
- an intermediate compound of structural formula (II), ( ⁇ )-trans 4-(4'-fluorophenyl)-3-ethoxycarbonyl-piperidin-2-one was synthesized which, upon reduction, produced (+)-trans 4-(4'-fluorophenyl)piperidine- 3-carbinol.
- 4-(4'-fluorophenyl)-3-ethoxycarbonyl-piperidin-2-one can be synthesized in the form of a substantially pure, crystalline solid having a melting point temperature in the range of about 140° to about 150°C and ( ⁇ )-trans configuration.
- alkyl includes both branched and straight-chain saturated aliphatic hydrocarbons; and the term “haloalkyl” means that the alkyl group is as defined above and substituted with one or more halogen atoms.
- Halogen refers to fluoro, chloro, bromo, or iodo.
- aryl refers to a carbocyclic aromatic moiety, such as phenyl, benzyl, naphthyl, and the like.
- alkali metal refers to sodium, potassium, lithium and the like. The inventive process is particularly well suited for the synthesis of 4- arylpiperidine-3-carbinols in (-)-trans configuration and derivatives thereof.
- Synthesis Scheme (1) comprises reacting a substituted benzaldehyde (Compound A) with acetonitrile in the presence of alkali metal hydroxide to a cinnamonitrile (Compound B); condensing Compound B with dialkyl malonate in a base, preferably an alkali metal alkoxide, and solvent, preferably an alkyl ester, medium to a diester intermediate of structural formula (I) (Compound C).
- a base preferably an alkali metal alkoxide
- solvent preferably an alkyl ester
- the alkyl group of each of the dialkyl malonate, alkali metal alkoxide and alkyl ester is the same to avoid the formation of mixed ester groups in the intermediate compound of structural formula (I).
- Synthesis Scheme (1) Also illustrated in Synthesis Scheme (1) is a further process embodiment of this invention which comprises hydrogenating Compound C to a (+)-trans monoester piperidin-2-one intermediate compound of structural formula (II) (Compound D); and further process embodiments of reducing Compound D to ( ⁇ )-trans arylpiperidine base (Compound E); alkylating Compound E to the ( ⁇ )-trans N-substituted compound (Compound F); and isolating from Compound F the all (-)-trans configured arylpiperidine carbinol (Compound G).
- Compound G can be isolated by resolving Compound F in two steps as illustrated in Synthesis Scheme (1). In step 1, Compound F is dissolved in a suitable solvent, preferably acetone.
- step 2 the crystallized salt is neutralized with aqueous base, preferably potassium hydroxide, to the (-)-trans- arylpiperidine carbinol (Compound G).
- Compound G can then be readily recovered and purified.
- X in each of Compounds A, B, C, D, E, F, and G is halogen, C r C 10 alkyl, C r C 10 alkoxy, C r C I0 haloalkyl, hydroxy, or hydrogen; each of R 2 and R 3 is C r C 4 alkyl and R 2 and R 3 are the same; and in each of Compounds F and G, R 4 is C,-C 10 .
- the inventive intermediates and inventive process greatly simplify the preparation from Compound E to the desired biologically active (-)-trans arylpiperidine carbinol compound and derivatives thereof, and 4-arylpiperidine-3 -carbinols in particular.
- Compound A is 4-fluorobenzaldehyde
- the alkali metal hydroxide is potassium hydroxide
- the diester malonate is diethyl malonate
- the base and solvent medium comprises sodium ethoxide and ethyl acetate, respectively
- Compound F is methyl-N-substituted as illustrated generally in synthesis Scheme (2).
- Compound G can be prepared as described above.
- Compound C is provided in Synthesis Scheme (2) as diethyl-[l- cyanomethyl-1 -(4 '-fluorophenyl)methyl] -malonate and recoverable in the form of a substantially pure, crystalline solid having a melting point temperature in the range of about 40° to about 55 °C, preferably in the range of about 45° to about 48 °C.
- Compound D is provided in Synthesis Scheme (2) as ( ⁇ )-trans 4-(4'-fluorophenyl)-3-ethoxycarbonyl-piperidin-2-one, which upon reduction produces ( ⁇ )-trans 4-(4'-fluorophenyl)piperidine-3-carbinol (Compound E).
- Compound D is also recoverable in the form of a substantially pure, crystalline solid having a distinct melting point temperature in the range of about 140° to about 150° C. Further advantages of this process are that Compound D so formed is in ( ⁇ )-trans configuration, and thus requires no additional work up to remove cis configured material.
- Powdered KOH (13.5 g, 85%) was suspended in acetonitrile (100 mL) solvent and mixed with stirring in a water bath at a temperature in the range of about 45 ° to about 50 °C.
- 4-Fluorobenzaldehyde (20 g) (Compound A) was dissolved in acetonitrile (30 mL) solvent and the resulting solution was added in a stream to the stirred mixture.
- the resulting reaction mixture was further stirred at the foregoing temperature for about 30 minutes after which the reaction mixture was quenched by pouring it into a beaker containing crushed ice (130 g).
- Mass Spectra Mass Spectra (CI, Methane); m/e (relative intensity): 148 (M + + lm 100), 272 (79), 254 (56), 125 (10), 109 (34). Analysis: Calculated for
- DiBiase Process A description of another process for the synthesis of 4-fluorocinnamonitrile can be found in DiBiase, S. A. et al., J. Organic Chemistry, 44(25), 4640-4649 (1979), the relevant disclosures of which are incorporated herein by reference (hereafter the "DiBiase Process").
- the DiBiase et al. process employs higher temperatures (reflux), a further extraction of the product with dichloromethane, drying over sodium sulfate and evaporation in vacuo at a bath temperature of 30°C and produced only a 50% yield. Therefore, the foregoing procedure was found to be an improvement over the DiBiase process, because it minimizes cinnamonitrile reaction in situ due to the lower temperature employed and affords easier workup of the product.
- Compound B was prepared by the DiBiase process described in Example 1. Sodium ethoxide (0.7 g) base was added to a solution of Compound B (1.47 g) dissolved in ethyl acetate (15 mL) solvent at ambient room temperature. Diethyl malonate (1.8 g) was added to the solution. The resulting reaction mixture was stirred overnight at ambient room temperature and then refluxed for 4 hours.
- the reaction mixture was then cooled to ambient room temperature and the procedure for obtaining Compound C from the cooled reaction mixture as described in Example 2 was followed, except that no acetic acid was employed.
- the title Compound C was provided in the form of a light yellow oil, which on standing, crystallized recovered as an off-white solid having a melting point in the range of about 44° to about 46°C (15.2 g, 73% yield).
- the chromatography data and spectral ⁇ -NMR data were substantially the same as the data obtained for Compound C prepared in Example 2.
- Example 3 Compound C of Example 3 (12.0 g) was reacted with activated Raney Ni (9.4 g, 50% wet) catalyst in methanol (150 mL), following the catalytic hydrogenation procedure of Example 3 except that a reaction period of about 48 hours (weekend) was employed.
- the title Compound D was recovered in the form of a crystalline white solid (9.0 g, 87% yield) having a melting point of 141-142°C.
- the TLC and HPLC results for Compound D were similar to those of Compound D prepared in Example 3.
- the recovered powder (1 g yield) had spectral characteristics ( ⁇ -NMR and Mass Spectra data) that were consistent with the data of the compound produced in Example 7.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU22004/00A AU2200400A (en) | 1998-12-22 | 1999-12-17 | Process for preparing arylpiperidine carbinol intermediates and derivatives |
EP99966475A EP1140832A4 (en) | 1998-12-22 | 1999-12-17 | Process for preparing arylpiperidine carbinol intermediates and derivatives |
HU0104036A HUP0104036A3 (en) | 1998-12-22 | 1999-12-17 | Process for preparing arylpiperidine carbinol intermediates and derivatives |
JP2000589515A JP2002533325A (en) | 1998-12-22 | 1999-12-17 | Process for producing aryl piperidine carbinol intermediates and derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21839398A | 1998-12-22 | 1998-12-22 | |
US09/218,393 | 1998-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000037443A1 true WO2000037443A1 (en) | 2000-06-29 |
Family
ID=22814930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/030365 WO2000037443A1 (en) | 1998-12-22 | 1999-12-17 | Process for preparing arylpiperidine carbinol intermediates and derivatives |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1140832A4 (en) |
JP (1) | JP2002533325A (en) |
AU (1) | AU2200400A (en) |
HU (1) | HUP0104036A3 (en) |
WO (1) | WO2000037443A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1242378A1 (en) * | 1999-12-23 | 2002-09-25 | SmithKline Beecham Corporation | Novel processes |
CN114437085A (en) * | 2020-11-03 | 2022-05-06 | 烟台弘邦医药科技有限公司 | Preparation method of Ruicapa intermediate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3912743A (en) * | 1973-01-30 | 1975-10-14 | Ferrosan As | 4-Phenylpiperidine compounds |
US4188396A (en) * | 1977-01-17 | 1980-02-12 | Ciba-Geigy Corporation | New phenylazacycloalkanes |
EP0190496A2 (en) * | 1984-12-13 | 1986-08-13 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
EP0802185A1 (en) * | 1996-04-15 | 1997-10-22 | Asahi Glass Company Ltd. | Process for producing piperidinecarbinols |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11240869A (en) * | 1997-12-22 | 1999-09-07 | Sumika Fine Chemicals Co Ltd | Lactam carboxylic acid derivative, its production and production of piperidine derivative using the same |
ES2137131B1 (en) * | 1998-02-06 | 2000-09-16 | Vita Invest Sa | DERIVATIVE OF PIPERIDINONE PROCEDURE FOR OBTAINING AND PROCEDURE FOR ITS USE. |
WO2000026187A1 (en) * | 1998-11-02 | 2000-05-11 | Synthon B.V. | Process for producing 4-arylpiperidine-3-carbinols and related compounds |
-
1999
- 1999-12-17 WO PCT/US1999/030365 patent/WO2000037443A1/en not_active Application Discontinuation
- 1999-12-17 AU AU22004/00A patent/AU2200400A/en not_active Abandoned
- 1999-12-17 JP JP2000589515A patent/JP2002533325A/en not_active Withdrawn
- 1999-12-17 HU HU0104036A patent/HUP0104036A3/en unknown
- 1999-12-17 EP EP99966475A patent/EP1140832A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3912743A (en) * | 1973-01-30 | 1975-10-14 | Ferrosan As | 4-Phenylpiperidine compounds |
US4188396A (en) * | 1977-01-17 | 1980-02-12 | Ciba-Geigy Corporation | New phenylazacycloalkanes |
EP0190496A2 (en) * | 1984-12-13 | 1986-08-13 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
EP0802185A1 (en) * | 1996-04-15 | 1997-10-22 | Asahi Glass Company Ltd. | Process for producing piperidinecarbinols |
Non-Patent Citations (4)
Title |
---|
JACQUES J., COLLET A., WILEN S. H.: "ENANTIOMERS, RACEMATES, AND RESOLUTIONS.", 1 January 1981, MALABAR, KRIEGER., US, article JACQUES J., COLLET A., WILEN S.H.: "DISSOCIABLE COMPOUNDS AND COMPLEXES. ENANTIOMERS, RACEMATES, AND RESOLUTIONS.", pages: 253/254., XP002923406, 020422 * |
KOELSCH C.F.: "A Synthesis of 4-phenylpiperidines", J. AM. CHEM. SOC.,, vol. 65, 1943, pages 2459 - 2460, XP002035294 * |
MOOS ET AL.: "Codeine Analogues. Synthesis of spiro(benzofuran-3(2H),4'-piperidines) and Octahydro-1H-benzofuro(3,2-e)isoquinolines", J. ORG. CHEM.,, vol. 46, no. 25, 1981, pages 5064 - 5074, XP002035519 * |
See also references of EP1140832A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1242378A1 (en) * | 1999-12-23 | 2002-09-25 | SmithKline Beecham Corporation | Novel processes |
EP1242378A4 (en) * | 1999-12-23 | 2003-01-15 | Smithkline Beecham Corp | Novel processes |
CN114437085A (en) * | 2020-11-03 | 2022-05-06 | 烟台弘邦医药科技有限公司 | Preparation method of Ruicapa intermediate |
Also Published As
Publication number | Publication date |
---|---|
EP1140832A1 (en) | 2001-10-10 |
JP2002533325A (en) | 2002-10-08 |
HUP0104036A3 (en) | 2003-04-28 |
HUP0104036A2 (en) | 2002-02-28 |
EP1140832A4 (en) | 2004-11-03 |
AU2200400A (en) | 2000-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6094961A (en) | Manufacture of pinacedole precursor and novel intermediate | |
US5039803A (en) | Process for preparing aryl-substituted piperidines | |
JPH07138231A (en) | Intermediate compound and its preparation | |
EP0986389B1 (en) | Novel process | |
RU2167868C2 (en) | Methods of synthesis of norbenzomorphane | |
US6833458B2 (en) | Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates | |
WO2000037443A1 (en) | Process for preparing arylpiperidine carbinol intermediates and derivatives | |
US6465689B1 (en) | Stereoselective processes for the preparation of gabapentin analogues | |
US6444822B1 (en) | Process for the preparation of 3-substituted 4-phenyl-piperidine derivative | |
EP1124802A1 (en) | Process for producing 4-arylpiperidine-3-carbinols and related compounds | |
KR20080027885A (en) | Process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-ylidene]methylpiperidine | |
CA2433605A1 (en) | Process for preparing (.plusmn.) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine | |
US20010053862A1 (en) | Process for preparing arylpiperidine carbinol intermediates and derivatives | |
JP2002537394A (en) | Method for producing paroxetine | |
US4497954A (en) | Cyclopentanone derivatives | |
EP1400511B1 (en) | Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor | |
KR100982720B1 (en) | Manufacturing Process of 2-Aminomalonamide as Intermediate for Producing 4-Carbamoyl-1-?-D-ribofuranosylimidazolium-5-olate | |
KR100354806B1 (en) | New intermediate for the preparation of amlodipine besylate and its process | |
JP2004131486A (en) | Method for producing n-alkoxycarbonylpiperidine derivative, raw material compound of the same and method for producing the same | |
KR20000063287A (en) | A new process for amlodipine besylate | |
KR20010013102A (en) | Novel Process | |
WO2005063707A1 (en) | Enantiospecific process for the preparation of paroxetine intermediate | |
KR20050000463A (en) | The Preparation Method of Optically Active Benzoxazine Derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 589515 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999966475 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999966475 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999966475 Country of ref document: EP |